A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

GLP-1 drugs achieve some of these effects by directly affecting the brain’s cravings for food, and that might also extend to ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

Patients taking liraglutide or semaglutide for weight loss report their alcohol intake dropping with the pounds-by as much as ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Medications like semaglutide and liraglutide may help to reduce the risk of heart attacks, strokes, and other major adverse ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...